The challenges of integrating molecular imaging into the optimization of cancer therapy

G. S. Patel, T. Kiuchi, K. Lawler, E. Ofo, G. O. Fruhwirth, M. Kelleher, E. Shamil, R. Zhang, P. R. Selvin, G. Santis, J. Spicer, N. Woodman, C. E. Gillett, P. R. Barber, B. Vojnovic, G. Kéri, T. Schaeffter, V. Goh, M. J. O'Doherty, P. A. EllisT. Ng

Research output: Contribution to journalReview article

Abstract

We review novel, in vivo and tissue-based imaging technologies that monitor and optimize cancer therapeutics. Recent advances in cancer treatment centre around the development of targeted therapies and personalisation of treatment regimes to individual tumour characteristics. However, clinical outcomes have not improved as expected. Further development of the use of molecular imaging to predict or assess treatment response must address spatial heterogeneity of cancer within the body. A combination of different imaging modalities should be used to relate the effect of the drug to dosing regimen or effective drug concentration at the local site of action. Molecular imaging provides a functional and dynamic read-out of cancer therapeutics, from nanometre to whole body scale. At the whole body scale, an increase in the sensitivity and specificity of the imaging probe is required to localise (micro)metastatic foci and/or residual disease that are currently below the limit of detection. The use of image-guided endoscopic biopsy can produce tumour cells or tissues for nanoscopic analysis in a relatively patient-compliant manner, thereby linking clinical imaging to a more precise assessment of molecular mechanisms. This multimodality imaging approach (in combination with genetics/genomic information) could be used to bridge the gap between our knowledge of mechanisms underlying the processes of metastasis, tumour dormancy and routine clinical practice. Treatment regimes could therefore be individually tailored both at diagnosis and throughout treatment, through monitoring of drug pharmacodynamics providing an early read-out of response or resistance.

Original languageEnglish (US)
Pages (from-to)603-631
Number of pages29
JournalIntegrative Biology
Volume3
Issue number6
DOIs
StatePublished - Jun 1 2011

Fingerprint

Molecular imaging
Molecular Imaging
Imaging techniques
Tumors
Neoplasms
Pharmacodynamics
Pharmaceutical Preparations
Tissue
Oncology
Biopsy
Medical imaging
Therapeutics
Image-Guided Biopsy
Cells
Monitoring
Drug Monitoring
Limit of Detection
Neoplasm Metastasis
Technology
Sensitivity and Specificity

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry

Cite this

Patel, G. S., Kiuchi, T., Lawler, K., Ofo, E., Fruhwirth, G. O., Kelleher, M., ... Ng, T. (2011). The challenges of integrating molecular imaging into the optimization of cancer therapy. Integrative Biology, 3(6), 603-631. https://doi.org/10.1039/c0ib00131g

The challenges of integrating molecular imaging into the optimization of cancer therapy. / Patel, G. S.; Kiuchi, T.; Lawler, K.; Ofo, E.; Fruhwirth, G. O.; Kelleher, M.; Shamil, E.; Zhang, R.; Selvin, P. R.; Santis, G.; Spicer, J.; Woodman, N.; Gillett, C. E.; Barber, P. R.; Vojnovic, B.; Kéri, G.; Schaeffter, T.; Goh, V.; O'Doherty, M. J.; Ellis, P. A.; Ng, T.

In: Integrative Biology, Vol. 3, No. 6, 01.06.2011, p. 603-631.

Research output: Contribution to journalReview article

Patel, GS, Kiuchi, T, Lawler, K, Ofo, E, Fruhwirth, GO, Kelleher, M, Shamil, E, Zhang, R, Selvin, PR, Santis, G, Spicer, J, Woodman, N, Gillett, CE, Barber, PR, Vojnovic, B, Kéri, G, Schaeffter, T, Goh, V, O'Doherty, MJ, Ellis, PA & Ng, T 2011, 'The challenges of integrating molecular imaging into the optimization of cancer therapy', Integrative Biology, vol. 3, no. 6, pp. 603-631. https://doi.org/10.1039/c0ib00131g
Patel GS, Kiuchi T, Lawler K, Ofo E, Fruhwirth GO, Kelleher M et al. The challenges of integrating molecular imaging into the optimization of cancer therapy. Integrative Biology. 2011 Jun 1;3(6):603-631. https://doi.org/10.1039/c0ib00131g
Patel, G. S. ; Kiuchi, T. ; Lawler, K. ; Ofo, E. ; Fruhwirth, G. O. ; Kelleher, M. ; Shamil, E. ; Zhang, R. ; Selvin, P. R. ; Santis, G. ; Spicer, J. ; Woodman, N. ; Gillett, C. E. ; Barber, P. R. ; Vojnovic, B. ; Kéri, G. ; Schaeffter, T. ; Goh, V. ; O'Doherty, M. J. ; Ellis, P. A. ; Ng, T. / The challenges of integrating molecular imaging into the optimization of cancer therapy. In: Integrative Biology. 2011 ; Vol. 3, No. 6. pp. 603-631.
@article{fb877f2747bf4a32aedd72790f37edf1,
title = "The challenges of integrating molecular imaging into the optimization of cancer therapy",
abstract = "We review novel, in vivo and tissue-based imaging technologies that monitor and optimize cancer therapeutics. Recent advances in cancer treatment centre around the development of targeted therapies and personalisation of treatment regimes to individual tumour characteristics. However, clinical outcomes have not improved as expected. Further development of the use of molecular imaging to predict or assess treatment response must address spatial heterogeneity of cancer within the body. A combination of different imaging modalities should be used to relate the effect of the drug to dosing regimen or effective drug concentration at the local site of action. Molecular imaging provides a functional and dynamic read-out of cancer therapeutics, from nanometre to whole body scale. At the whole body scale, an increase in the sensitivity and specificity of the imaging probe is required to localise (micro)metastatic foci and/or residual disease that are currently below the limit of detection. The use of image-guided endoscopic biopsy can produce tumour cells or tissues for nanoscopic analysis in a relatively patient-compliant manner, thereby linking clinical imaging to a more precise assessment of molecular mechanisms. This multimodality imaging approach (in combination with genetics/genomic information) could be used to bridge the gap between our knowledge of mechanisms underlying the processes of metastasis, tumour dormancy and routine clinical practice. Treatment regimes could therefore be individually tailored both at diagnosis and throughout treatment, through monitoring of drug pharmacodynamics providing an early read-out of response or resistance.",
author = "Patel, {G. S.} and T. Kiuchi and K. Lawler and E. Ofo and Fruhwirth, {G. O.} and M. Kelleher and E. Shamil and R. Zhang and Selvin, {P. R.} and G. Santis and J. Spicer and N. Woodman and Gillett, {C. E.} and Barber, {P. R.} and B. Vojnovic and G. K{\'e}ri and T. Schaeffter and V. Goh and O'Doherty, {M. J.} and Ellis, {P. A.} and T. Ng",
year = "2011",
month = "6",
day = "1",
doi = "10.1039/c0ib00131g",
language = "English (US)",
volume = "3",
pages = "603--631",
journal = "Integrative biology : quantitative biosciences from nano to macro",
issn = "1757-9694",
publisher = "Royal Society of Chemistry",
number = "6",

}

TY - JOUR

T1 - The challenges of integrating molecular imaging into the optimization of cancer therapy

AU - Patel, G. S.

AU - Kiuchi, T.

AU - Lawler, K.

AU - Ofo, E.

AU - Fruhwirth, G. O.

AU - Kelleher, M.

AU - Shamil, E.

AU - Zhang, R.

AU - Selvin, P. R.

AU - Santis, G.

AU - Spicer, J.

AU - Woodman, N.

AU - Gillett, C. E.

AU - Barber, P. R.

AU - Vojnovic, B.

AU - Kéri, G.

AU - Schaeffter, T.

AU - Goh, V.

AU - O'Doherty, M. J.

AU - Ellis, P. A.

AU - Ng, T.

PY - 2011/6/1

Y1 - 2011/6/1

N2 - We review novel, in vivo and tissue-based imaging technologies that monitor and optimize cancer therapeutics. Recent advances in cancer treatment centre around the development of targeted therapies and personalisation of treatment regimes to individual tumour characteristics. However, clinical outcomes have not improved as expected. Further development of the use of molecular imaging to predict or assess treatment response must address spatial heterogeneity of cancer within the body. A combination of different imaging modalities should be used to relate the effect of the drug to dosing regimen or effective drug concentration at the local site of action. Molecular imaging provides a functional and dynamic read-out of cancer therapeutics, from nanometre to whole body scale. At the whole body scale, an increase in the sensitivity and specificity of the imaging probe is required to localise (micro)metastatic foci and/or residual disease that are currently below the limit of detection. The use of image-guided endoscopic biopsy can produce tumour cells or tissues for nanoscopic analysis in a relatively patient-compliant manner, thereby linking clinical imaging to a more precise assessment of molecular mechanisms. This multimodality imaging approach (in combination with genetics/genomic information) could be used to bridge the gap between our knowledge of mechanisms underlying the processes of metastasis, tumour dormancy and routine clinical practice. Treatment regimes could therefore be individually tailored both at diagnosis and throughout treatment, through monitoring of drug pharmacodynamics providing an early read-out of response or resistance.

AB - We review novel, in vivo and tissue-based imaging technologies that monitor and optimize cancer therapeutics. Recent advances in cancer treatment centre around the development of targeted therapies and personalisation of treatment regimes to individual tumour characteristics. However, clinical outcomes have not improved as expected. Further development of the use of molecular imaging to predict or assess treatment response must address spatial heterogeneity of cancer within the body. A combination of different imaging modalities should be used to relate the effect of the drug to dosing regimen or effective drug concentration at the local site of action. Molecular imaging provides a functional and dynamic read-out of cancer therapeutics, from nanometre to whole body scale. At the whole body scale, an increase in the sensitivity and specificity of the imaging probe is required to localise (micro)metastatic foci and/or residual disease that are currently below the limit of detection. The use of image-guided endoscopic biopsy can produce tumour cells or tissues for nanoscopic analysis in a relatively patient-compliant manner, thereby linking clinical imaging to a more precise assessment of molecular mechanisms. This multimodality imaging approach (in combination with genetics/genomic information) could be used to bridge the gap between our knowledge of mechanisms underlying the processes of metastasis, tumour dormancy and routine clinical practice. Treatment regimes could therefore be individually tailored both at diagnosis and throughout treatment, through monitoring of drug pharmacodynamics providing an early read-out of response or resistance.

UR - http://www.scopus.com/inward/record.url?scp=79959199867&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959199867&partnerID=8YFLogxK

U2 - 10.1039/c0ib00131g

DO - 10.1039/c0ib00131g

M3 - Review article

C2 - 21541433

AN - SCOPUS:79959199867

VL - 3

SP - 603

EP - 631

JO - Integrative biology : quantitative biosciences from nano to macro

JF - Integrative biology : quantitative biosciences from nano to macro

SN - 1757-9694

IS - 6

ER -